Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | CCR3 | P51677 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2401885 | 0.89 | SIGMAR1 (0.76) | SIGMAR1CCR3 | |
| SCHEMBL10388555 | 0.88 | SIGMAR1 (0.68) | SIGMAR1MEN1KMT2ACCR3 | |
| SCHEMBL10387884 | 0.86 | SIGMAR1 (0.68) | SIGMAR1MEN1KMT2ACCR3 | |
| SCHEMBL13150782 | 0.86 | SLC6A3 (0.83) | SLC6A3SIGMAR1HTR1ADRD2MEN1 | |
| SCHEMBL6056974 | 0.86 | SLC6A3 (0.83) | SLC6A3SIGMAR1HTR1ADRD2MEN1 | |
| SCHEMBL14407778 | 0.86 | SLC6A3 (0.83) | SLC6A3SIGMAR1HTR1ADRD2MEN1 | |
| SCHEMBL7264546 | 0.86 | SLC6A3 (0.83) | SLC6A3SIGMAR1HTR1ADRD2MEN1 | |
| SCHEMBL5407959 | 0.84 | KCNH2 (0.59) | SLC6A3KCNH2 | |
| SCHEMBL3035813 | 0.84 | SLC6A3 (0.61) | SLC6A3SIGMAR1HTR1ADRD2MEN1 | |
| SCHEMBL31709325 | 0.84 | SLC6A3 (0.61) | SLC6A3SIGMAR1HTR1ADRD2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111511730-B | Amide substituted indole compounds useful as TLR inhibitors | 百时美施贵宝公司 | 2023-07-25 | — | — | CN | claimed |
| CN-111511730-A | Amide substituted indole compounds useful as T L R inhibitors | 百时美施贵宝公司 | 2020-08-07 | — | — | CN | claimed |
| CN-102143953-A | Pyrimidines, triazines and their use as pharmaceutical agents | UNIV NOTTINGHAM | 2011-08-03 | — | — | CN | claimed |
| CN-111511730-B | Amide substituted indole compounds useful as TLR inhibitors | 百时美施贵宝公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-111511730-A | Amide substituted indole compounds useful as T L R inhibitors | 百时美施贵宝公司 | 2020-08-07 | — | — | CN | disclosed |
| US-20170152226-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2017-06-01 | — | — | US | disclosed |
| WO-2016008010-A1 | FUNCTIONALISED AND SUBSTITUTED CARBAZOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2016-01-21 | — | — | WO | disclosed |
| CN-103524442-A | Pyrimidine compound, triazine compound and application thereof as medicine | LE SUN PHARMACEUTICALS LTD | 2014-01-22 | — | — | CN | disclosed |
| CN-102143953-B | Pyrimidines, triazines and their use as pharmaceutical agents | LE SUN PHARMACEUTICALS LTD | 2013-12-25 | — | — | CN | disclosed |
| CN-1926121-B | Thiazole derivatives and uses thereof | MERCK SERONO SA | 2012-06-13 | — | — | CN | disclosed |
| CN-102143953-A | Pyrimidines, triazines and their use as pharmaceutical agents | UNIV NOTTINGHAM | 2011-08-03 | — | — | CN | disclosed |
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | BRANE DISCOVERY S.R.L. (IT) | 2009-11-05 | — | — | US | disclosed |
| CN-1319532-C | Use of N- (indolylcarbonyl) piperazine derivatives | MERCK PATENT GMBH (DE) | 2007-06-06 | — | — | CN | disclosed |
| CN-1926121-A | Thiazole derivatives and uses thereof | APPLIED RESEARCH SYSTEMS (AN) | 2007-03-07 | — | — | CN | disclosed |
| CN-1589147-A | Use of N-(indolecarbonyl-)piperazine derivatives | MERCK PATENT GMBH (DE) | 2005-03-02 | — | — | CN | disclosed |
| EP-1228041-A2 | INDOLE DERIVATIVES AND THEIR USE AS 5HT2A LIGANDS | MERCK PATENT GmbH (DE) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001007434-A2 | INDOLE DERIVATIVES AND THEIR USE AS 5HT2A LIGANDS | MERCK PATENT GMBH (DE) | 2001-02-01 | — | — | WO | disclosed |
| CN-1022632-C | Carboxamide compounds, process for preparing same and pharmaceutical composition containing same | OTSUKA PHARMA CO LTD (JP) | 1993-11-03 | — | — | CN | disclosed |
| US-4971957-A | ANTILIPEMIC AGENTS, ANTICHOLESTEROL AGENTS, BENZENECARBOXAMIDOPHOSPHONATES OR BENZENETHIOCARBOXAMIDOPHOSPHONATES | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1990-11-20 | — | — | US | disclosed |
| CN-1040029-A | Carboxylic acid amide compounds and preparation method thereof and contain the pharmaceutical composition of this carboxylic acid amine compound | OTSUKA PHARMA CO LTD (JP) | 1990-02-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | OGFRL1, OPRL1, ORMDL3 | SLC6A3 436/4885SIGMAR1 20/4885HTR1A 14/4885 |
| US-20170152226-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | SLC6A3 1941/4885SIGMAR1 2620/4885HTR1A 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.